Clinical trials: Cisplatin, completed
Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Station-Specific Lymph Node Metastasis After Neoadjuvant Chemoimmunotherapy for Middle Thoracic Esophageal Squamous Cell Carcinoma
Neoadjuvant chemoimmunotherapy (NCIT) is increasingly used for locally advanced esophageal squamous cell carcinoma (ESCC). However, the station-specific distribution of residual lymph node metastasis after NCIT remains…
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Metastasis
- Trial name
- NCT07902544
- Volunteers
- 717 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Early Triple Negative Breast Cancer
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy
The purpose of this study is to assess efficacy of platinum-based neoadjuvant chemotherapy in correlation with BRCA1-associated DNA repair dysfunction in patients with early triple negative breast cancer.
- Trial name
- NCT01672671
- Testing
- Doxorubicin, Paclitaxel, Cisplatin
- Where
- Russia
- Volunteers
- 41 people
- Sponsor
- Russian Academy of Medical Sciences
Thrombocytopaenia
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or…
- Trial name
- NCT01147809
- Testing
- Eltrombopag olamine
- Where
- 86 sites in United States, Belgium and 11 more
- Volunteers
- 130 people
- Sponsor
- GlaxoSmithKline
Malignant Tumors
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
This trial is an open and multicenter phase Ib/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.
- Trial name
- NCT05516914
- Testing
- LBL-007 Injection, Tislelizumab Injection, Cisplatin Injection
- Where
- 15 sites in China
- Volunteers
- 98 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Nasopharyngeal Cancer
Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma
This study evaluates whether some patients with nasopharyngeal carcinoma but with low risk of distant metastasis can be treated with only radiotherapy and concomitant chemotherapy but without additional adjuvant chemotherapy.
- Trial name
- NCT03175939
- Testing
- Radiotherapy, Cisplatin, 5-FU
- Volunteers
- 263 people
- Sponsor
- Sun Yat-sen University
Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma
Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma
Neoadjuvant therapy of cisplatin-based chemotherapy has been proved to improve prognosis of muscle invasive UTUC patients in several studies.
- Trial name
- NCT04672330
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 16 people
- Sponsor
- RenJi Hospital
Carcinoma, Non-Small-Cell Lung
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if participants with Stage IV NSCLC have a better outcome when treated with IMC-1121B in combination with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin than…
- Trial name
- NCT01160744
- Testing
- IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6)
- Where
- 53 sites in United States, Belgium and 4 more
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer
Neoadjuvant chemotherapy (NAC) is increasingly used for early-stage operable breast cancer. Response of breast cancer to NAC is correlated with survival: patients who obtain greatest survival advantage are those who attain…
- Trial name
- BERNAQ (NCT02365805)
- Testing
- Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel, Epirubicin + Cisplatin + Fluorouracil, Docetaxel + Ciclofosfamide
- Where
- 7 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Testicular Germ Cell Tumor
Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004077
- Testing
- cisplatin, ifosfamide, paclitaxel
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Medical Research Council
Metastatic Breast Cancer
Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes
This is an open label, two arms, randomized, unblinded phase 2 study in patients with locally advanced or metastatic breast cancer who have been previously treated with anthracycline with/without taxane based regimen in the…
- Trial name
- NCT00192101
- Testing
- gemcitabine, cisplatin
- Where
- Saudi Arabia
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Cisplatin Adverse Reaction, Hearing Loss Ototoxic
Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer
Introduction. Cisplatin-induced ototoxicity is a very frequent event and its consequences can cause a lot of deterioration in patients.
- Trial name
- NCT03400709
- Testing
- N Acetylcysteine
- Where
- Chile
- Volunteers
- 45 people
- Sponsor
- Hospital San Juan de Dios, Santiago
Stomach Neoplasms
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and antitumor response of ramucirumab in combination with platinum/fluoropyrimidine regimens in Japanese participants with advanced…
- Trial name
- NCT02359058
- Testing
- Ramucirumab, Capecitabine, Cisplatin
- Where
- 4 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Head and Neck Cancer Patients, Lean Body Mass
Lean Body Mass in Head and Neck Cancer Patients During Cisplatin-based Chemoradiation
The goal of this clinical trial is to investigate the changes in body composition in head and neck cancer patients during treatment.
- Conditions
- Head and Neck Cancer Patients, Lean Body Mass, Body Composition Changes
- Trial name
- NCT05890859
- Testing
- DXA scan, Physical testing
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Department of Public Health, Denmark
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Drugs used in chemotherapy, such as 3-AP and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT00081276
- Testing
- triapine, cisplatin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC
Primary objective of this study is to evaluate the efficacy of gemcitabine and cisplatin as first line therapy in patients with triple-negative MBC. 80 patients will be treated into this study.
- Trial name
- NCT00601159
- Testing
- gemcitabine and cisplatin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Breast Cancer
Combination Chemotherapy for Metastatic Breast Cancer
The purpose of this study is to determine the objective tumor response of the first-line therapy combination of gemcitabine and cisplatin in patients with metastatic breast cancer
- Trial name
- NCT00191815
- Testing
- Gemcitabine, cisplatin
- Where
- 2 sites in Germany, Russia
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer
The aim of this study is to evaluate the tolerability (in terms of drug delivery and toxicity) of four cycles of adjuvant docetaxel plus cisplatin in patients with completely resected stage IB-II Non-Small Cell Lung Cancer.
- Trial name
- TOLEDO (NCT00434668)
- Testing
- cisplatin/docetaxel, cisplatin/vinorelbine
- Where
- 3 sites in Belgium
- Volunteers
- 99 people
- Sponsor
- University Hospital, Antwerp
Nasopharyngeal Neoplasms, Carcinoma
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
The primary objective is to estimate the Complete Response rate of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) compared to cisplatin-5-fluorouracil (CF) in the Induction treatment of Nasopharyngeal Carcinoma…
- Trial name
- NCT00565448
- Testing
- docetaxel, cisplatin, 5-fluorouracil
- Where
- 26 sites in Algeria, Brazil and 12 more
- Volunteers
- 75 people
- Sponsor
- Sanofi
Stomach Neoplasms
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
The purpose of the study is to determine the safe and tolerable doses of sunitinib given together with either cisplatin and capecitabine or oxaliplatin and capecitabine in patients who have advanced gastric cancer who have not…
- Trial name
- NCT00555620
- Testing
- capecitabine, oxaliplatin, sunitinib malate
- Where
- 3 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase 1 clinical study to evaluate the bioavailability of tislelizumab subcutaneous (SC) injection in the first-line treatment of participants with advanced or metastatic non-small cell lung…
- Trial name
- NCT06091943
- Testing
- Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet
- Where
- 15 sites in China, Georgia and 1 more
- Volunteers
- 62 people
- Sponsor
- BeiGene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.